Allogeneic hematopoietic stem cell transplantation for XXXX .

@entity1 @entity6582 @entity82 @entity786 @entity4018 @entity1863 @entity4407
Fifty-six @entity1 , 10 to 66 years of age, with @entity4018 ( @entity4018 ) or end-stage @entity6582 vera or @entity4407 received allogeneic hematopoietic cell transplants from related (n = 36) or unrelated (n = 20) donors. Forty-four @entity1 were prepared with @entity1863 plus @entity786 and 12 with total body irradiation plus chemotherapy. The source of stem cells was marrow in 33 and peripheral blood in 23 @entity1 . All but 3 @entity1 achieved engraftment. While 50 @entity1 showed complete donor chimerism, 3 @entity1 were found to be mixed chimeras at 26, 48, and 86 months after transplantation, respectively. Two @entity1 died from relapse/progressive disease, and 18 died from other causes. There are 36 @entity1 surviving at 0.5 to 11.6 (median, 2.8) years, for a 3-year Kaplan-Meier estimate of 58% (CI, 43%-73%). Dupriez score, cytogenetic abnormalities, and degree of marrow @entity82 were the most significant risk factors for posttransplantation mortality. @entity1 conditioned with a regimen of @entity1863 targeted to plasma levels of 800 to 900 ng/mL plus @entity786 had a higher probability of survival (76% [CI, 62%-91%]) than other @entity1 . Results with unrelated donors were comparable with those with HLA-identical sibling transplants. Thus, allogeneic hematopoietic cell transplantation offers long-term relapse-free survival for @entity1 with @entity4018 .
